Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 219

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 219
---
” has the meaning ascribed thereto in NI 62-104; |

| (www) | “Laws” means, with respect to any person, property, transaction, event or other matter, any                                                                                                              
 foreign or domestic constitution, treaty, law, statute, regulation, code, ordinance, principle of common law or equity, rule, municipal by-law or Order relating or applicable to such person, property, 
 transaction, event or other matter;                                                                                                                                                                      |

| (xxx) | “Lease” means any lease, sublease, license, occupancy agreement, or other agreement pursuant                                                          
 to which the Company or the Subsidiary is vested with rights to use or occupy the Leased Properties, as amended, modified or supplemented or renewed; |

| (yyy) | “Leased Property” means any real property leased, subleased, licensed or otherwise used or 
 occupied by the Company or the Subsidiary;                                                 |

| (zzz) | “Liabilities” means liabilities of the Company and its Subsidiary determined in accordance                                                                                                           
 with GAAP, provided, that, for purposes hereof, the liabilities of the Company and its Subsidiary shall not include any amounts otherwise deducted from Closing Net Cash pursuant to Section 1.1(z). |

| (aaaa) | “Material Adverse Change” means any fact or state of facts, circumstance, change, effect,                                                                                                                                                
 occurrence or event that (i) either individually or in the aggregate prevents or materially delays, or individually or in the aggregate would reasonably be expected to prevent or materially delay the consummation of the Contemplated 
 Transaction; or (ii) individually or in the aggregate is, or would reasonably be expected to be, material and adverse to the financial condition, assets or liabilities (contingent or otherwise) of the Company and its Subsidiary,     |

A-11

| taken as a whole, other than any such change, effect, occurrence or event directly or indirectly relating to or resulting from: |

| (A) | conditions generally affecting the industries in which the Company and its Subsidiary operate in jurisdictions 
 in which the Company and its Subsidiary carry on business;                                                     |

| (B) | changes to applicable Laws, GAAP or changes in accounting or regulatory requirements generally applicable to 
 the industries in which such Party and its Subsidiary operate as a whole;                                    |

| (C) | changes to the general economic,